Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Biosciences company provides ECO-4601 update
August 15th, 2005
Ecopia BioSciences, Inc., (EIA) reviewed recent operating highlights and announced its financial results for the second quarter ended May 31, 2005. Commenting on Ecopia's progress for the second quarter, Dr. Pierre Falardeau, president and CEO, said: "We are very enthusiastic about these new results showing that ECO-4601 is also active against breast and prostate cancers. These cancers affect almost 400,000 patients per year in the United States alone. Our immediate focus remains glioma, an unmet medical need that can get us to the market very quickly. Our operations for this quarter and the remainder of 2005 remain focused on filing ECO-4601's IND [investigational new...
Source: Pharma Business Week (2005-08-15)
|
